Abstract
Age-adjusted cardiovascular disease (CVD) prevalence rates are significantly lower in Japan than in the United States. Our aim was to compare CVD risk in participants in Fukuoka and Framingham. We measured glucose, insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), small dense LDL-C, and triglycerides in men and women from Fukuoka (n = 1108), and age (median, 53 years) and gender-matched subjects from Framingham (n = 1101). Blood pressure, body mass index, use of medications, and history of CVD were also assessed. CVD prevalence rates were more than 6-fold higher in Framingham men and women than their Fukuoka counterparts (P < .001). Median body mass index, LDL-C, insulin levels, and insulin resistance assessment in Fukuoka men and women were significantly (P < .01) lower than in Framingham; however, diabetes prevalence in Fukuoka men was significantly (P < .01) higher than in Framingham men, whereas female rates were similar, as were levels of systolic blood pressure. High-density lipoprotein cholesterol and surprisingly small dense LDL-C levels were significantly (P < .001) higher in Fukuoka than in Framingham. Standard risk factors do not account for the large differences in CVD preva...Continue Reading
References
Sep 1, 1979·American Journal of Epidemiology·W B KannelW P Castelli
Jan 1, 1991·American Heart Journal·K M AndersonW B Kannel
Jun 1, 1994·Circulation·A KitamuraT Sankai
Aug 1, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·K G Alberti, P Z Zimmet
Dec 3, 2002·Archives of Internal Medicine·Hanna Bloomfield RubinsJames W Anderson
Apr 30, 2003·Diabetes Care·Sander J RobinsUNKNOWN Veterans Affairs HDL Intervention Trial (VA-HIT)
Jul 26, 2003·Diabetes Research and Clinical Practice·Steven M Haffner
Sep 19, 2003·Journal of Human Hypertension·B F ZhouUNKNOWN INTERMAP Research Group
May 27, 2004·Diabetes Care·Tara M WallaceDavid R Matthews
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
May 1, 2010·Clinical Chemistry·Masumi AiErnst J Schaefer
Sep 25, 2010·Atherosclerosis·Seiko OtokozawaErnst J Schaefer
Nov 26, 2010·Journal of Atherosclerosis and Thrombosis·Hiroshige ItakuraUNKNOWN JELIS Investigators
Jul 12, 2011·Atherosclerosis·Masumi AiErnst J Schaefer
Mar 9, 2012·Circulation·Nancy R CookPaul M Ridker
Jun 5, 2012·International Journal of Cardiology·Norihiro FurusyoJun Hayashi
Jan 10, 2013·PloS One·Karin B GastOlaf M Dekkers
Nov 14, 2013·Circulation·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Nov 14, 2013·Circulation·David C GoffGordon F Tomaselli
Nov 16, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Michael Y TsaiAlan T Remaley
Feb 22, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Ron C HoogeveenChristie M Ballantyne
Jan 13, 2015·Lancet·UNKNOWN Cholesterol Treatment Trialists' (CTT) CollaborationAnthony Keech
Oct 16, 2015·Current Diabetes Reports·Markku Laakso
Nov 11, 2016·Scientific Reports·Hiroaki IkezakiNorihiro Furusyo
Citations
Feb 7, 2019·Journal of Atherosclerosis and Thrombosis·Hung HsuMasumi Ai
Apr 14, 2020·Journal of Atherosclerosis and Thrombosis·Hiroaki IkezakiErnst J Schaefer
Jun 20, 2019·Frontiers in Endocrinology·Veronica Maria TagiFrancesco Chiarelli
Oct 30, 2020·Journal of Atherosclerosis and Thrombosis·Marie NakamuraMasumi Ai
Dec 23, 2021·BMJ Open·Hiroaki IkezakiJun Hayashi